Na Wang1, Yili Zhu1, Ying Wu1, Bo Huang1, Junhua Wu1, Ruiguang Zhang2, Jun Fan3, Xiu Nie4. 1. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. 2. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China. 3. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. fanjun0915@sina.com. 4. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. niexiuyishi@126.com.
Abstract
BACKGROUND: Mesenchymal epithelial transition (MET) overexpression has been reported in approximately 50-60% of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers. However, the prognostic significance of MET overexpression has not been established in advanced lung adenocarcinoma (ADC) patients with EGFR-sensitive mutations. METHODS: A retrospective study was performed on a total of 406 treatment-naïve advanced ADC patients with EGFR mutation detection and MET expression information. EGFR mutations were detected by next-generation sequencing or amplification refractory mutation system-polymerase chain reaction. Immuno-histochemistry staining of MET expression was evaluated by H-score and overexpression was defined as an H-score ≥ 200. Overall survival (OS) and progression-free survival (PFS) were analyzed according to MET expression. RESULTS: Among the 406 patients, 208 patients had EGFR mutations, including 102 exon 19_del mutations, 94 L858R mutations and 12 other types of mutations. Of 110 patients with concomitant EGFR mutations and MET overexpression, 61 (59.8%) patients had 19_del mutations, 44 (46.8%) patients had L858R mutations and five (41.7%) patients had others. Patients with MET overexpression had a markedly shorter PFS and OS than patients with MET H-score < 200 in the EGFR L858R mutation subgroup (median PFS: 12 versus 26 months, p = 0.001; median OS: 24 versus 32 months, p = 0.038), whereas no significant difference was observed in 19_del mutation subgroup. Multivariate Cox analysis showed that MET overexpression was an independent poor prognostic factor for PFS and OS in patients with the L858R mutations (HR = 3.064, 95% CI 1.705-5.507, p < 0.001; HR = 2.043, 95% CI 1.000-4.172; p = 0.049), rather than 19_del. CONCLUSIONS: MET overexpression is a poor prognostic factor for advanced ADC patients with the EGFR L858R mutation.
BACKGROUND: Mesenchymal epithelial transition (MET) overexpression has been reported in approximately 50-60% of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers. However, the prognostic significance of MET overexpression has not been established in advanced lung adenocarcinoma (ADC) patients with EGFR-sensitive mutations. METHODS: A retrospective study was performed on a total of 406 treatment-naïve advanced ADC patients with EGFR mutation detection and MET expression information. EGFR mutations were detected by next-generation sequencing or amplification refractory mutation system-polymerase chain reaction. Immuno-histochemistry staining of MET expression was evaluated by H-score and overexpression was defined as an H-score ≥ 200. Overall survival (OS) and progression-free survival (PFS) were analyzed according to MET expression. RESULTS: Among the 406 patients, 208 patients had EGFR mutations, including 102 exon 19_del mutations, 94 L858R mutations and 12 other types of mutations. Of 110 patients with concomitant EGFR mutations and MET overexpression, 61 (59.8%) patients had 19_del mutations, 44 (46.8%) patients had L858R mutations and five (41.7%) patients had others. Patients with MET overexpression had a markedly shorter PFS and OS than patients with MET H-score < 200 in the EGFR L858R mutation subgroup (median PFS: 12 versus 26 months, p = 0.001; median OS: 24 versus 32 months, p = 0.038), whereas no significant difference was observed in 19_del mutation subgroup. Multivariate Cox analysis showed that MET overexpression was an independent poor prognostic factor for PFS and OS in patients with the L858R mutations (HR = 3.064, 95% CI 1.705-5.507, p < 0.001; HR = 2.043, 95% CI 1.000-4.172; p = 0.049), rather than 19_del. CONCLUSIONS: MET overexpression is a poor prognostic factor for advanced ADC patients with the EGFR L858R mutation.
Authors: Robin Guo; Lynne D Berry; Dara L Aisner; Jamie Sheren; Theresa Boyle; Paul A Bunn; Bruce E Johnson; David J Kwiatkowski; Alexander Drilon; Lynette M Sholl; Mark G Kris Journal: J Thorac Oncol Date: 2019-06-20 Impact factor: 15.609
Authors: Fred R Hirsch; Giorgio V Scagliotti; James L Mulshine; Regina Kwon; Walter J Curran; Yi-Long Wu; Luis Paz-Ares Journal: Lancet Date: 2016-08-27 Impact factor: 79.321
Authors: Paul K Paik; Enriqueta Felip; Remi Veillon; Hiroshi Sakai; Alexis B Cortot; Marina C Garassino; Julien Mazieres; Santiago Viteri; Helene Senellart; Jan Van Meerbeeck; Jo Raskin; Niels Reinmuth; Pierfranco Conte; Dariusz Kowalski; Byoung Chul Cho; Jyoti D Patel; Leora Horn; Frank Griesinger; Ji-Youn Han; Young-Chul Kim; Gee-Chen Chang; Chen-Liang Tsai; James C-H Yang; Yuh-Min Chen; Egbert F Smit; Anthonie J van der Wekken; Terufumi Kato; Dilafruz Juraeva; Christopher Stroh; Rolf Bruns; Josef Straub; Andreas Johne; Jürgen Scheele; John V Heymach; Xiuning Le Journal: N Engl J Med Date: 2020-05-29 Impact factor: 91.245
Authors: Keunchil Park; Eric B Haura; Natasha B Leighl; Paul Mitchell; Catherine A Shu; Nicolas Girard; Santiago Viteri; Ji-Youn Han; Sang-We Kim; Chee Khoon Lee; Joshua K Sabari; Alexander I Spira; Tsung-Ying Yang; Dong-Wan Kim; Ki Hyeong Lee; Rachel E Sanborn; José Trigo; Koichi Goto; Jong-Seok Lee; James Chih-Hsin Yang; Ramaswamy Govindan; Joshua M Bauml; Pilar Garrido; Matthew G Krebs; Karen L Reckamp; John Xie; Joshua C Curtin; Nahor Haddish-Berhane; Amy Roshak; Dawn Millington; Patricia Lorenzini; Meena Thayu; Roland E Knoblauch; Byoung Chul Cho Journal: J Clin Oncol Date: 2021-08-02 Impact factor: 50.717